At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
Net Sales are expected to increase by 13.4 percent Y-o-Y (up 3.1 percent Q-o-Q) to Rs 1,895.3 crore, according to ICICI Direct.
Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.
Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.
Net Sales are expected to increase by 31.6 percent Y-o-Y (down 0.1 percent Q-o-Q) to Rs. 1,538.7 crore, according to Kotak.
Net Sales are expected to increase by 32.4 percent Y-o-Y (up 6 percent Q-o-Q) to Rs. 1,400.7 crore, according to Sharekhan.
Net Sales are expected to increase by 30.7 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs. 1,382.4 crore, according to ICICI Direct.
“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
Net Sales are expected to increase by 19.1 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,154 crore, according to Sharekhan.
Net Sales are expected to increase by 28.6 percent Y-o-Y (up 10.8 percent Q-o-Q) to Rs. 1,245.4 crore, according to ICICI Direct.
Net Sales are expected to increase by 24.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 1,162 crore, according to Kotak.
We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.
EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.
Net Sales are expected to increase by 8.4 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 1018.9 crore, according to Kotak.
In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.
Operating profit during the quarter may drop 20% to Rs 211.3 crore and margin may contract by 560 basis points to 21.2 percent year-on-year.
Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.
Operating profit is expected to jump 20 percent year-on-year to Rs 254.4 crore and margin may expand 240 basis points to 23.5 percent in the quarter ended March 2017.
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Biopharmaceutical company Biocon's third quarter profit is likely to increase 38 percent year-on-year to Rs 142 crore and revenue may grow 15.5 percent to Rs 965.7 crore.
Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
Biocon's profit is expected to fall 55 percent to Rs 137.2 crore in July-September quarter compared with Rs 305.9 crore in year-ago period, according to average of estimates of analysts polled by CNBC-TV18.
Net Sales are expected to increase by 3.5 percent Q-o-Q (up 21.5 percent Y-o-Y) to Rs 1017 crore, according to Centrum.
Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.
The most important news that everyone will be tracking is when we submit dossiers in Europe and US for insulin Glargine and that as we have indicated will happen this fiscal, says Kiran Mazumdar Shaw